XENT · Intersect Ent, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.57M | - | $24.40M | $27.35M | $24.33M | - | $22.72M | $9.78M | $19.83M | - |
| Cost of Revenue | $7.69M | - | $5.09M | $8.33M | $8.46M | - | $7.84M | $7.36M | $6.41M | - |
| Gross Profit | $13.88M | - | $19.31M | $19.02M | $15.87M | - | $14.88M | $2.42M | $13.42M | - |
| R&D | $9.39M | - | $6.72M | $6.36M | $6.37M | - | $4.55M | $4.02M | $5.15M | - |
| SG&A | $28.03M | - | $29.47M | $28.73M | $28.08M | - | $21.70M | $19.50M | $26.20M | - |
| Total Operating Expenses | $40.56M | - | $36.19M | $35.09M | $34.45M | - | $26.25M | $23.52M | $31.35M | - |
| D&A | $403.0K | - | - | - | $1.20M | - | - | - | $496.0K | - |
| Operating Income | ($26.67M) | - | ($16.88M) | ($16.07M) | ($18.57M) | - | ($11.38M) | ($21.09M) | ($17.93M) | - |
| Interest Expense | $2.05M | - | $1.76M | $1.41M | $0 | - | $886.0K | $486.0K | - | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | - | - | - | - |
| Net Income | ($28.80M) | - | ($31.85M) | ($16.60M) | ($20.03M) | - | ($11.46M) | ($23.12M) | ($17.53M) | - |
| EPS - Basic | ($0.85) | - | ($0.95) | ($0.71) | - | - | - | - | - | - |
| EPS - Diluted | ($0.85) | - | ($0.95) | ($0.71) | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $25.59M | $38.40M | $59.18M | $21.36M | $14.37M | $13.52M | $56.89M | $29.46M | $34.19M | $20.65M |
| Accounts Receivable | $13.24M | $17.33M | $14.40M | $15.99M | $14.58M | $14.59M | $11.88M | $7.65M | $10.31M | $19.11M |
| Inventory | $17.74M | $18.60M | $20.06M | $15.06M | $13.22M | $12.05M | $11.16M | $14.01M | $17.05M | $17.00M |
| Accounts Payable | $9.18M | $8.89M | $10.25M | $7.63M | $6.94M | $6.04M | $4.59M | $2.62M | $4.91M | $4.06M |
| Current Assets | $87.48M | $106.00M | $119.86M | $92.37M | $102.29M | $118.17M | $156.66M | $159.46M | $117.61M | $129.05M |
| Total Assets | $127.39M | $146.87M | $227.97M | $200.86M | $210.44M | $227.38M | $173.14M | $176.78M | $135.90M | $147.90M |
| Current Liabilities | $46.41M | $57.16M | $50.79M | $45.40M | $43.54M | $44.25M | $19.78M | $14.13M | $17.74M | $18.94M |
| Long-term Debt | $142.61M | $127.35M | $111.66M | - | - | - | - | - | - | - |
| Total Liabilities | $221.42M | $215.94M | $211.75M | $159.23M | $158.18M | $160.37M | $91.76M | $87.67M | $28.04M | $29.84M |
| Stockholders' Equity | ($94.03M) | ($69.07M) | $16.21M | $41.63M | $52.26M | $67.01M | $81.38M | $89.11M | $107.86M | $118.06M |
| Retained Earnings | ($491.51M) | ($462.71M) | ($371.56M) | ($339.71M) | ($323.11M) | ($303.07M) | ($282.88M) | ($271.41M) | ($248.29M) | ($230.76M) |
Cash Flow
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($26.86M) | - | - | - | ($16.77M) | - | - | - | ($5.96M) | - |
| Investing Cash Flow | ($2.70M) | - | - | - | $17.63M | - | - | - | $16.40M | - |
| Financing Cash Flow | $15.82M | - | - | - | $1.12M | - | - | - | $3.10M | - |
| CapEx | $153.0K | - | - | - | $467.0K | - | - | - | $137.0K | - |
| Free Cash Flow | ($27.01M) | - | - | - | ($17.24M) | - | - | - | ($6.09M) | - |
Ratios
| Metric | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 64.4% | - | 79.2% | 69.5% | 65.2% | - | 65.5% | 24.8% | 67.7% | - |
| Operating margin | -123.6% | - | -69.2% | -58.8% | -76.3% | - | -50.1% | -215.7% | -90.4% | - |
| EBITDA margin | -121.8% | - | - | - | -71.4% | - | - | - | -87.9% | - |
| Net margin | -133.5% | - | -130.5% | -60.7% | -82.3% | - | -50.5% | -236.4% | -88.4% | - |
| Free cash flow margin | -125.2% | - | - | - | -70.9% | - | - | - | -30.7% | - |
| FCF / Net income | 0.94 | - | - | - | 0.86 | - | - | - | 0.35 | - |
| R&D / Revenue | 43.5% | - | 27.5% | 23.3% | 26.2% | - | 20.0% | 41.1% | 26.0% | - |
| SG&A / Revenue | 129.9% | - | 120.8% | 105.1% | 115.4% | - | 95.5% | 199.4% | 132.1% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -22.6% | - | -14.0% | -8.3% | -9.5% | - | -6.6% | -13.1% | -12.9% | - |
| Return on equity | 30.6% | - | -196.4% | -39.9% | -38.3% | - | -14.1% | -25.9% | -16.3% | - |
| Return on invested capital | -43.4% | - | -10.4% | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.88 | 1.85 | 2.36 | 2.03 | 2.35 | 2.67 | 7.92 | 11.28 | 6.63 | 6.82 |
| Quick ratio | 1.50 | 1.53 | 1.97 | 1.70 | 2.05 | 2.40 | 7.36 | 10.29 | 5.67 | 5.92 |
| Cash ratio | 0.55 | 0.67 | 1.17 | 0.47 | 0.33 | 0.31 | 2.88 | 2.08 | 1.93 | 1.09 |
| Leverage | ||||||||||
| Debt / Equity | -1.52 | -1.84 | 6.89 | - | - | - | - | - | - | - |
| Debt / Assets | 1.12 | 0.87 | 0.49 | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -13.0x | - | -9.6x | -11.4x | - | - | -12.8x | -43.4x | - | - |
| Equity multiplier | -1.35 | -2.13 | 14.06 | 4.82 | 4.03 | 3.39 | 2.13 | 1.98 | 1.26 | 1.25 |
| Liabilities / Assets | 1.74 | 1.47 | 0.93 | 0.79 | 0.75 | 0.71 | 0.53 | 0.50 | 0.21 | 0.20 |
| Efficiency | ||||||||||
| Asset turnover | 0.17 | - | 0.11 | 0.14 | 0.12 | - | 0.13 | 0.06 | 0.15 | - |
| Inventory turnover | 0.43 | - | 0.25 | 0.55 | 0.64 | - | 0.70 | 0.53 | 0.38 | - |
| Days sales outstanding | 224d | - | 215d | 213d | 219d | - | 191d | 286d | 190d | - |
| Days inventory outstanding | 842d | - | 1439d | 660d | 571d | - | 519d | 695d | 971d | - |
| Days payable outstanding | 436d | - | 735d | 334d | 300d | - | 214d | 130d | 279d | - |
| Cash conversion cycle | 630d | - | 919d | 539d | 490d | - | 496d | 851d | 881d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -11.3% | - | 7.4% | 179.6% | 22.7% | - | -5.6% | -63.3% | -25.7% | - |
| Revenue CAGR (3y) | -6.8% | - | -0.4% | 1.3% | -0.5% | - | 0.6% | -25.8% | -1.1% | - |
| Revenue CAGR (5y) | 1.1% | - | 5.7% | 7.2% | 7.8% | - | 9.8% | -8.4% | 8.2% | - |
| Gross profit growth (YoY) | -12.5% | - | 29.8% | 684.9% | 18.3% | - | -22.4% | -88.8% | -39.1% | - |
| Operating income growth (YoY) | -43.6% | - | -48.3% | 23.8% | -3.6% | - | 15.1% | -75.2% | -56.7% | - |
| Net income growth (YoY) | -43.8% | - | -177.8% | 28.2% | -14.2% | - | 10.8% | -103.1% | -62.3% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -56.7% | - | - | - | -182.9% | - | - | - | -26.0% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | -80.1% | -53.3% | -51.6% | -43.2% | -26.6% | -24.5% | -9.2% | -2.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$106.75M totalPropel Family Of Products$91.12M · 85.4%
Sinuva$9.07M · 8.5%
Ven Sure CUBEAnd Accessories$6.56M · 6.1%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Intersect ENT against the 5 most active filers in the same SIC group.